First look at Verve study data offer base editing ‘proof of principle’
Bio Pharma Dive
NOVEMBER 12, 2023
Early clinical trial results are the first for a base editing treatment and show Verve’s therapy can substantially lower cholesterol levels by editing the genes of liver cells.
Let's personalize your content